Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia

International Journal of Cancer

Volumn 105, Issue 1, 2003, Pages 123-129

  Wang, Zejing ^a   Corey, Eva ^a   Hass, G Michael ^b   Higano, Celestia S ^a   True, Lawrence D ^c   Wallace Jr , David ^a   Tisdale, Michael J ^d   Vessella, Robert L ^a,c,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Matritech Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d ASTON UNIVERSITY   (United Kingdom)

^e Puget Sound VA Health Care System   (United States)

Author keywords

Cachexia; Human cachexia associated factor; Metastasis; Prostate cancer (CaP)

Indexed keywords

HUMAN CACHEXIA ASSOCIATED PROTEIN; MESSENGER RNA; PROTEIN; PROTEOLYSIS INDUCING FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CACHEXIA; CADAVER DONOR; CANCER GROWTH; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DISSEMINATED CANCER; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; BONE NEOPLASMS; CACHEXIA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; IN SITU HYBRIDIZATION; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TIME FACTORS; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

EID: 0037457669     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11035     Document Type: Article

References (36)

1. Tisdale MJ. Cancer anorexia and cachexia. Nutrition. 2001;17:438-42.
2. Argiles JM, Meijsing SH, Pallares-Trujillo J, Guirao X, Lopez-Soriano FJ. Cancer cachexia: a therapeutic approach. Med Res Rev 2001;21:83-101.
3. van Eys J. Effect of nutritional status on responses to therapy. Cancer Res 1982;42:747s-53s.
4. DeWys W. Management of cancer cachexia. Semin Oncol 1985;12: 452-60.
5. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000;16:1009-12.
6. Tisdale MJ. Wasting in cancer. J Nutr 1999;129:243S-6S.
7. Kotler DP. Cachexia. Ann Intern Med 2000;133:622-34.
8. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000;16:1013-4.
9. Nelson KA. Modern management of the cancer anorexia-cachexia syndrome. Curr Oncol Rep 2000;2:362-8.
10. Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E, Fujioka N, Mai M, Kasahara T, Fujimoto Ouchi K, Mori K, Tanaka Y, Matsushima K. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 1995;55:921-7.
11. Davis MP, Dickerson D. Cachexia and anorexia: cancer's covert killer. Support Care Cancer, 2000;8:180-7.
12. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92:1684-8.
13. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin ASJ. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363-6.
14. Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 2002;290:1-10.
15. Iguchi H, Onuma E, Sato K, Sato K, Ogata E. Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. Int J Cancer 2001;94:24-7.
16. Gadducci A, Cosio S, Fanucchi A, Genazzani AR. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Res 2001;21:2941-7.
17. Khan S, Tisdale MJ. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor. Int J Cancer 1999;80:444-7.
18. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001;7:846-53.
19. Ishiko O, Hirai K, Nishimura S, Sumi T, Honda K, Deguchi M, Tatsuta I, Ogita S. Elimination of anemia-inducing substance by cyclic plasma perfusion of tumor-bearing rabbits. Clin Cancer Res 1999;5:2660-5.
20. Ishiko O, Sumi T, Yoshida H, Hirai K, Honda K, Matsumoto Y, Ogita S. Anemia-inducing substance is related to elimination of lipolytic hyperactivity by cyclic plasma perfusion in human cancer cachexia. Nutr Cancer 2000;37:169-72.
21. McDevitt TM, Todorov PT, Beck SA, Khan SH, Tisdale MJ. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Res 1995;55:1458-63.
22. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
23. Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997;76:606-13.
24. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000;87:53-8.
25. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 2001;84:1599-601.
26. Watchorn TM, Waddell I, Ross JA. Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol Endocrinol Metab 2002;282:763-9.
27. Akerblom IE, Murry LE. Human cachexia associated protein. Palo Alto, CA: Incyte Pharmaceuticals. Inc., 1998. 628413(5,834,192).
28. Buhler KR, Corey E, Stray JE, Vessella RL. Study of free and complexed prostate-specific antigen in mice bearing human prostate cancer xenografts. Prostate 1998;36:194-200.
29. Barton BE, Cullison J, Jackson J, Murphy T. A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice. Proc Soc Exp Biol Med 2000;223:190-7.
30. Jorgensen M, Hummel R, Bevort M, Andersson AM, Shakkebaek NE, Leffers H. Detection of oesrogenic chemicals by assaying the expression level of oestrogen regulated genes. APMIS, 1998;106:245-51.
31. Smith HJ, Lorite MJ, Tisdale MJ. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res 1999;59:5507-13.
32. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 2001;85:297-302.
33. Pfitzemaier J, Vessella RL, Higano CS, Noteboom JL, Wallace D, Corey E. Elevation of cytokine levels in cachectic prostate cancer patients. Cancer, in press.
34. Cunningham TJ, Jing H, Wang Y, Hodge L. Calreticulin binding and other biological activities of survival peptide Y-P30 including effects of systemic treatment of rats. Exp Neurol 2000;163:457-68.
35. Cunningham TJ, Jing H, Akerblom I, Morgan R, Fisher TS, Neveu M. Identification of the human cDNA for new survival evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp Neurol 2002;177:32-9.
36. Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, Schirle M, Schroeder K, Blin N, Meier F, Rassner G, Garbe C. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2001;2:1133-7.